Association of serum inhibin a with pre-eclampsia: An observational cohort study with propensity score matching.
cohort study
inhibin A
pre-eclampsia
pregnancy
propensity score matching
risk factor
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
revised:
31
10
2023
received:
05
06
2023
accepted:
13
11
2023
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
aheadofprint
Résumé
To assess whether serum inhibin A at 14-20 weeks of gestation is associated with the occurrence of pre-eclampsia. A retrospective cohort study using propensity score matching was conducted on 11 682 singleton pregnant women with established deliveries at the Obstetrics and Gynecology Hospital of Fudan University between January 2017 and July 2019. We investigated serum inhibin A levels at 14-20 weeks of gestation and calculated the relative risk between inhibin A and pre-eclampsia by multifactorial logistic regression analysis. Smoothed, fitted curves were used to observe the effect of inhibin A in relation to the occurrence of pre-eclampsia. The risk of pre-eclampsia occurrence increased with elevated serum inhibin A. After full adjustment for confounders, the risk ratio for pre-eclampsia in the group of pregnant women with high inhibin A was 2.92 (95% confidence interval [CI] 2.08-4.11) compared with those with normal inhibin A. The results of sensitivity analysis suggested a consistent effect of inhibin A on the risk of pre-eclampsia in different populations. Elevated serum inhibin A at 14-20 weeks of gestation is associated with pre-eclampsia and may provide an early warning signal for pregnancy outcomes associated with pre-eclampsia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 81902131
Organisme : Shanghai Municipal Health Bureau
ID : 20204Y0404
Organisme : Shanghai Clinical Research Center for Gynecological Diseases
ID : 22MC1940200
Organisme : Shanghai Urogenital System Diseases Research Center
ID : 2022ZZ01012
Informations de copyright
© 2023 International Federation of Gynecology and Obstetrics.
Références
de Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. Hum Reprod Update. 2002;8:529-541.
Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260-267.
Florio P, Cobellis L, Luisi S, et al. Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol Cell Endocrinol. 2001;180:123-130.
Yu J, Shixia CZ, Wu Y, Duan T. Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound Obst Gyn. 2011;37:528-533.
Brown LF, Shearing CH, Tydeman G. Stability of inhibin A and unconjugated oestriol in the second trimester of pregnancy. Ann Clin Biochem. 2011;48(Pt 1):72-74.
Yue CY, Zhang CY, Ni YH, Ying CM. Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome? PLoS One. 2020;15(5):e0232634.
D'Anna R, Baviera G, Corrado F, Leonardi I, Buemi M, Jasonni VM. Is mid-trimester maternal serum inhibin-A a marker of pre-eclampsia or intrauterine growth restriction? Acta Obstet Gyn Scan. 2002;81:540-543.
Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenatal Diag. 2003;23:990-996.
Shen Z, Cai LY, Suprapto IS, Shenoy P, Zhou X. Placental and maternal serum inhibin a in patients with pre-eclampsia and small-for-gestational-age. J Obstet Gynaecol Re. 2011;37:1290-1296.
Singnoi W, Wanapirak C, Sekararithi R, Tongsong T. A cohort study of the association between maternal serum inhibin-A and adverse pregnancy outcomes: a population-based study. BMC Pregnancy Childbirth. 2019;19:124.
Xu YT, Shen MH, Jin AY, Li H, Zhu R. Maternal circulating levels of transforming growth factor-β super family and its soluble receptors in hypertensive disorders of pregnancy. BJOG-Int J Obstet Gy. 2017;137:246-252.
Yue CY, Zhang CY, Ying CM. Serum markers in quadruple screening associated with adverse pregnancy outcomes: a case-control study in China. Clin Chim Acta. 2020;511:278-281.
De Kat AC, Hirst J, Woodward M, Kennedy S, Peters SA. Prediction models for pre-eclampsia: a systematic review. Pregnancy Hypertens. 2019;16:48-66.
Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066-1074.
Tuuli MG, Odibo AO. The role of serum markers and uterine artery Doppler in identifying at-risk pregnancies. Clin Perinatol. 2011;38(1):1-19. v.
Eche S, Mackraj I, Moodley J. Circulating fetal and total cell-free DNA, and sHLAG in black South African women with gestational hypertension and pre-eclampsia. Hypertens Pregnancy. 2017;36(4):295-301.
Nerenberg KA, Park AL, Vigod SN. Long-term risk of a seizure disorder after eclampsia. Obstet Gynecol. 2017;130(6):1327-1333.
Yue CY, Gao JP, Zhang CY, Ni YH, Ying CM. Development and validation of a nomogram for the early prediction of pre-eclampsia in pregnant Chinese women. Hypertens Res. 2021;44:417-425.